

28

29

30 **Single dose of intra-muscular platelet rich plasma reverses the increase in plasma iron levels**

31

in exercise-induced muscle damage : A pilot study32 **Abstract**

33 *Objectives:* Platelets rich plasma (PRP) therapy is widely used in enhancing the recovery of skeletal
34 muscle from injury. However, the impact of intramuscular delivery of PRP on hematologic and
35 biochemical responses has not been fully elucidated in exercise-induced muscle damage (EIMD).

36 *Design:* Moderately active male volunteers participated in this study and were assigned to a
37 control group (CONTROL, n=6) and platelet rich plasma administration group (PRP, n=6).The
38 subjects performed exercise with a load of 80 % one repetition maximum (1RM) maximal
39 voluntary contraction of the elbow flexors until point of exhaustion of the non-dominant arm was
40 reached. The arms were treated with saline or autologous PRP post-24h EIMD. Venous blood
41 samples were obtained in the morning to establish a base-line value and 1-4 days post-exercise and
42 were analyzed for serum ferritin, iron, iron binding capacity (IBC), creatinine kinase (CK), lactate
43 dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT).

44 *Results:* The baseline levels of plasma iron, ferritin, IBC, CK, LDH, AST and ALT were similar in
45 both the control and PRP groups. However, 24 h following exercise a significant increase in these
46 parameters was observed in both groups between 1-4 days during the recovery period. Interestingly,
47 PRP administration decreased plasma iron levels compared to the control on the second day post-
48 exercise. Plasma IBC increased in PRP group from day 2 to 4 post exercise compared to the control
49 group whilst PRP administration had no effect on plasma ferritin, CK, AST, ALT and LDH.

50 *Conclusions:* Acute exhaustive exercise increased muscle damage markers, including plasma iron,
51 IBC and ferritin levels, indicating muscle damage induced by exercise. PRP administration

52 improves inflammation by reversing the increase in the iron levels post-exercise without displaying
53 any myotoxicity and may have a role to play in the recovery of exercise-induced muscle damage.

54 **Key Words:** platelet-rich plasma, plasma iron, ferritin, exercise-induced muscle damage

55 **1. Introduction**

56 Recently platelet-rich plasma (PRP), an autologous derivative of whole blood containing a
57 supraphysiological concentration of platelets has gained increasing popularity in both the scientific
58 literature and the wider media for its potential application in the treatment of traumatic
59 musculoskeletal and sports-related injuries, cancer biology, and dermatology. In addition, it has
60 been reported that PRP administration may improve recovery from tendon and muscle injuries^{1,2}.
61 Biologic healing utilizes the normal mechanisms for tissue repair and incorporates these at the site
62 of injury. Blood components such as platelets migrate to the injury site and play an important role in
63 tissue repair. Platelets contain various growth factors and cytokines that initiate and promote
64 healing by stimulating cell migration, cell proliferation, angiogenesis, and matrix. Other important
65 bioactive factors released from platelets include histamine and serotonin and these platelet growth
66 factors enhance DNA synthesis, chemotaxis, angiogenesis, increase collagen deposition, and
67 stimulate synthesis of extracellular matrix³.

68 It is well established that an unaccustomed and strenuous exercise in the trained and
69 untrained individual can induce skeletal muscle damage⁴; this phenomenon is commonly known as
70 “exercise-induced muscle damage” (EIMD) and is determined by the type, intensity and duration of
71 exercise⁵. Moreover, in sports, the eccentric/concentric type of exercise has been used as a specific
72 training model for muscle strength improvement during training sessions. However, symptoms of
73 EIMD include reduced muscular force, increased stiffness, swelling delayed onset muscle soreness
74 (DOMS), and an increased blood activity of muscle proteins such as creatine kinase (CK > 10,000
75 IU/L)⁴, alanine transaminase (ALT)⁶, aspartate transaminase (AST)⁶, lactate dehydrogenase

76 activity⁷ and this may have a negative impact on performance⁴. Moreover, EIMD initiates an
77 inflammatory response associated with secondary muscle damage and remodeling⁸ since during the
78 acute phase, both neutrophils and phagocytic macrophages can release reactive oxygen and nitrogen
79 species and remove debris by phagocytosis⁹. Moreover, recent studies have reported the levels of
80 the iron-regulatory hormone hepcidin are also increased after exercise¹⁰⁻¹². Hepcidin is a liver-
81 produced peptide hormone, up-regulated in response to elevated iron levels and the inflammatory
82 cytokine interleukin-6 (IL-6)^{13,14} and an increase in hepcidin levels usually occurs as a homeostatic
83 response to inflammatory stimuli namely the IL-6 or elevated iron levels¹³. Peeling et al. reported
84 that inflammation, hemolysis, serum iron, ferritin, and urinary hepcidin were elevated in the high
85 intensity interval post- running session¹¹. As such, the post-exercise hepcidin response is likely to
86 be homeostatic in nature, to help control and reduce the elevated levels of serum iron resulting from
87 the exercise-induced hemolysis¹⁵.

88 Many studies have been published proposing various methods for treating DOMS, including
89 cryotherapy, anti-inflammatory medication, stretching, hyperbaric oxygen, homeopathy, ultrasound,
90 L-carnitine, rest, light exercise and electromagnetic shields¹⁶⁻²¹. For example, non-steroidal anti-
91 inflammatory drugs (NSAIDs) are routinely prescribed to alleviate EIMD-related symptoms and
92 restore normal physical function of the muscle²². However, it has been reported that NSAIDs act by
93 blocking COX and thus they may have a detrimental effect on muscle regeneration and super-
94 compensation²⁰. Moreover, there is strong to moderate evidence that intramuscularly injected local
95 anaesthetics and NSAIDs are myotoxic. The administration of PRP has also been reported to induce
96 myotoxicity, however the evidence is conflicting and further studies are required to confirm this as
97 well as the possible myotoxic effects of corticosteroids²³. Furthermore, clinical and
98 histopathological studies have shown the potential myotoxicity of intramuscular injections in both
99 animals and humans^{24,25}, resulting in pain at the injection site and histopathological changes of

100 inflammation, necrosis and fibrosis^{24,25}. Besides histological changes, the local plasma creatine
101 kinase (CK) concentration is the most commonly used valid marker for skeletal muscle
102 myotoxicity²⁶⁻²⁸. There is conflicting evidence regarding the myotoxicity of intramuscular PRP
103 injections. Two studies used an animal muscle injury model and reported increased signs of
104 regeneration, less necrosis and less granulomatous tissue in the muscles injected with, PRP^{29,30} and
105 autologous conditioned serum (ACS)³¹ than in control muscles on histological evaluation for up to 2
106 weeks. However, information regarding the myotoxicity of intramuscular PRP injection or the
107 cross-talk between hematologic and biochemical response has not been reported in exercise-induced
108 muscle damage. Therefore, we hypothesized that intramuscular PRP injection might improve
109 inflammation and beneficial effect on DOMS and muscle damage induced by exercise without
110 myotoxicity effects. The objective of the present study was to investigate whether the myotoxicity
111 effects of the intramuscular PRP injection can provide an effective recovery strategy for attenuating
112 DOMS and muscle damage induced by high-intensity muscle exercise in humans.

113

114 **2. Methods**

115 *2.1. Study Design*

116 Twelve moderately active male volunteers participated in this randomized double-blind
117 placebo-controlled trial to verify the effects of the intramuscular PRP injection on hematologic,
118 biochemical response and myotoxicity on muscle recovery after an eccentric/concentric exercise.
119 Subjects were randomly placed into two groups: PRP (n=6) and CONTROL (n=6) and they had not
120 been involved in any regular weight-training program and had no history of injury to the arm,
121 shoulder and elbow region. The nature and the risks of the experimental procedures were explained
122 to the subjects, and signed informed consent to participate in the study was obtained. Before the
123 test session, participants were examined and checked by the use of routine blood analysis by a

124 medically qualified practitioner. Ethical approval was obtained from The Balikesir University
125 Medical Faculty Ethics Committee (2013/14) and each participant gave written informed consent
126 prior to the study.

127 *2.2. Muscle Damage Exercise Protocol*

128 For the exercise-induced muscle damage test, subjects were seated on a bench with their arm
129 positioned in front of their body and resting on a padded support, such that their shoulder was
130 secured at a flexion angle of 0.79 rad (45°) and their forearm was maintained in the supinated
131 position throughout the exercise. Subjects were repeatedly weight-loaded upon dumbbell lowering
132 to achieve a 80% of maximum voluntary contraction (MVC), 2-min rest between the sets of elbow
133 extension from the flexed position at 90° to fully extended position slowly over 5 s, until exhaustion
134 was experienced. The subjects were also given verbal encouragement by the investigator to
135 maintain constant speed throughout the procedure. They were instructed to continue their normal
136 activities and to abstain from any strenuous exercise at least two weeks before the experiment.
137 Moreover, they were asked to continue their usual food intake, not to change the amount or
138 frequency of dietary meat and not to use any dietary supplements, anti-inflammatory drugs, or
139 anything else that could affect muscle soreness and damage until the end of the study.

140 *2.3. Platelet-rich plasma and placebo*

141 Each participant based on computerized randomization lists to either receive placebo
142 (saline) injection or PRP injection in non-dominant arms with post-24h DOMS exercise. PRP
143 preparation was obtained from eight millilitres of peripheral blood which was drawn from the
144 dominant arm and the samples were centrifuged for 9 minutes at 3500 revolutions per minute (H-
145 19F, RegenCentrigel) according to manufacturers recommendation (Regen ACR-C, Regen Lab,
146 Switzerland). Subsequently, 4 ml of PRP was injected using a 20-gauge needle into the pain full
147 region of the non-dominant arm under sterile aseptic conditions. This kit produces 4 mL of PRP

148 from 8 mL citrated blood. Therefore final platelet concentration is approximately ≤ 2 fold over
149 whole blood platelet concentration. Platelet recovery is reported to be $> 95\%$ and a leukocyte
150 recovery of 58% .

151 Venous blood samples were collected pre-, and 4 days post-exercise, and analyzed for complete
152 blood counts (WBC, RBC, Hb) , serum ferritin, iron (Fe), iron binding capacity (IBC), creatinine
153 kinase (CK), lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine
154 aminotransferase (ALT) as markers of muscle damage and inflammation.

155 *2.4. Hematological analysis*

156 For analyses of serum iron (Fe), iron binding capacity (IBC), and ferritin blood samples
157 were collected without any additive and after centrifugation sera were stored at -20°C until analyzed.
158 Iron and IBC were measured spectrophotometrically in an Advia 1800 analyzer (Siemens
159 Healthcare, Erlangen, Germany) and ferritin was measured by immunoturbidimetric assay in an
160 Olympus AU400 analyzer (Beckman Coulter, CA, USA).

161 *2.5. Biochemical analysis*

162 Following centrifugation at $825 \times g$ for 10 min, serum was analyzed for ALT, AST, CK and
163 LDH activities using commercially available kits in a chemistry autoanalyser (Cobas Integra 800;
164 Roche Diagnostic GmbH; Mannheim, Germany).

165 *2.6. Statistical Analysis*

166 All calculations were performed using SPSS software (SPSS Inc, Chicago, Illinois, USA).
167 The values of serum Fe, IBC, ferritin, ALT, AST, LDH, and CK are presented as raw values as the
168 area under the curve (AUC) during the experimental period. The AUC was calculated as the sum of
169 four or five trapezoid areas separated by each supplement time point. Two-way mixed model
170 analyses of variance (2 group X 5 times) with repeated measures were used. Differences in
171 continuous variables between groups were assessed using Independent t-test and between multiple

172 points within the same group were analyzed using student's paired t-test. Data are expressed as
173 means \pm SE and the level of significance was set at $p < 0.05$.

174

175 **3. Results**

176 There was no difference in body weight, height, age and exercise performance had no
177 significant differences between PRP and CONTROL (Table 1, $p > 0.05$). The baseline values for
178 plasma Fe, IBC, ferritin, AST, ALT, LDH and CK values were similar between the CONTROL and
179 the PRP administered group ($p > 0.05$). However, 24 h following exercise, the plasma Fe, IBC,
180 AST, ALT, LDH and CK values significantly increased in the CONTROL and the PRP
181 administered group on day 1 to 4 post exercise muscle damage ($P < 0.01$, Fig. 1-5). Acute
182 exhaustive muscle exercise also increased the plasma ferritin levels in control and PRP group ($P <$
183 0.001 and $P < 0.05$) respectively, Fig.3. Interestingly, PRP administration decreased plasma iron
184 levels ($P = 0.002$) compared to the control group but this was only observed on the day 2-3 post-
185 exercise-induced muscle damage (Fig. 1). Moreover, plasma IBC levels were increased in PRP
186 group from day 1 to 4 post exercise compared to control group ($P < 0.05$, Fig. 2). In contrast, PRP
187 administration had no effect on plasma ferritin (Fig. 3), AST, ALT (Fig. 4), LDH and CK levels
188 (Fig. 5).

189 **Insert Table 1 here**

190 **Insert Figure 1 here**

191 **Insert Figure 2 here**

192 **Insert Figure 3 here**

193 **Insert Figure 4 here**

194 **Insert Figure 5 here**

195

196 4. Discussion

197 In this paper we report the effect of single dose of intra-muscular platelet rich plasma on
198 iron levels in in exercise-induced muscle damage. This was a pilot study in which 6 subjects
199 participated in the control group and test group. Acute exhaustive exercise increased muscle
200 damage markers, including plasma iron, IBC and ferritin levels were increased confirming exercise-
201 induced muscle damage. PRP administration resulted in improved muscle recovery from injury
202 without displaying any myotoxicity. Many methods have been utilised for the treatment of DOMS,
203 including cryotherapy, anti-inflammatory medication, stretching, hyperbaric oxygen, homeopathy,
204 ultrasound, L-carnitine, rest, light exercise and electromagnetic shields¹⁶⁻¹⁹. Inflammatory
205 conditions have been essentially treated by the use of non-steroidal anti-inflammatory drugs
206 (NSAIDs) although they are ineffective in reducing muscle pain and do not increase muscle
207 performance during DOMS^{20-22,32-34}. As an alternative to conventional treatments, platelet-rich
208 therapy has been applied due to its potential in accelerating muscle healing and reducing a player's
209 injury time. As far as we are aware, this study is the first to examine the effect of intramuscular PRP
210 administration on DOMS and muscle damage markers also post exercise-induced muscle damage
211 during the recovery period in healthy human volunteers. Importantly, our results show that the acute
212 exhaustive muscle exercise increased the plasma iron, IBC and ferritin level in both groups. Our
213 findings on plasma iron, IBC and ferritin response to acute exhaustive exercise are in agreement
214 with previous reports¹⁰⁻¹³. which also reported an increase in serum iron, IBC and ferritin levels
215 which was linked to the intensity of the exercise. It seems the increase in serum ferritin levels also
216 led to an increase in plasma iron and hepcidin levels. A majority of publications have reported an
217 elevated hepcidin levels 24 h post exercise, preceded by acute increase in serum iron and
218 inflammation parameters^{10-13, 35}. However, we did not measure the post- exercise hepcidin levels in
219 this study. The present study indicates that post-exercise serum iron, IBC and ferritin levels are

220 induced as a result of inflammatory response due to exhaustive muscle exercise. Speculatively,
221 acute exhaustive exercise increased the free iron that enters the plasma and has a reduction-
222 oxidation (redox) potential, which may promote free radical formation as a result of Fenton and
223 Harber–Weiss reactions and can result in oxidative damage to tissues³⁶. Interestingly, in this study it
224 was observed that PRP administration reversed the observed increase in plasma iron level due to
225 muscle damage 2-3 days post-exercise. Furthermore, plasma IBC levels were up-regulated in PRP
226 group from day 1 to 4 post-exercise. On the other hand PRP administration depressed the plasma
227 ferritin levels during the recovery phase compared to control values, but did not reach statistical
228 significance. These results are novel and to the best of our knowledge, no data exists concerning the
229 acute effect of intramuscular PRP administration on plasma iron, IBC and ferritin levels parameters
230 during recovery period in an acute exercise-induced muscle damage model. In general, related
231 studies have reported that PRP treatment has anti-inflammatory properties through its effects on the
232 canonical nuclear factor κ B signalling pathway in multiple cell types including synoviocytes,
233 macrophages and chondrocytes³⁷. In addition, PRP treatment has suppressed tendon cell
234 inflammation *in vitro* and *in vivo*, marked by the upregulation of COX-1, COX-2 and mPGES-1
235 expression with highly PGE2 production³⁸. Additionally, the present study demonstrated that
236 intramuscular PRP injection plays a key role as an anti-inflammatory by suppressing effect of
237 increased free iron in plasma during the muscle damage recovery. Evidently, we have previously
238 shown that elbow flexors muscle strength peak torque values were improved after PRP
239 administration when compared to the control arm, this occurred on the same day (second day)
240 when the serum iron level declined post exercise-induced muscle damage (*Unpublished data*).

241 Serum CK concentration is the most sensitive indicator of muscle damage and it begins to
242 rise approximately 2-12 h after the exhaustive exercise. Exhaustive physical exercise increases
243 serum enzyme activities such as CK, AST, LDH and ALT hence these are considered as markers

244 for the muscular damage derived from intense exercise³⁹. The increased activities of CK and LDH
245 in serum after exhausted exercise could act as signals, attracting neutrophils to the damaged muscle
246 and initiating the inflammatory response. The maintenance of high CK activities after recovery
247 could be an indicator of muscle repair⁴⁰⁻⁴². Our results demonstrate that CK, AST, ALT and LDH
248 levels increased post-exercise during the DOMS period in both groups, indicating muscle damage.
249 On the other hand, CK concentration is the most commonly used valid marker for skeletal muscle
250 myotoxicity in the intramuscular injections²⁶⁻²⁸. Although intramuscular PRP injections are
251 commonly used, there is only limited evidence base for myotoxicity in animal models²⁹⁻³¹ and
252 these studies reported increased signs of regeneration of the muscle whilst necrosis and
253 granulomatous tissue was decreased in the muscle injected with PRP when compared to the
254 control, however, no response to CK levels was reported in these studies²⁹⁻³¹. Limited human
255 studies have been shown that intramuscular injection of lidocaine⁴³ and bupivacaine (20 ml)⁴⁴ lead
256 to an increase in CK levels. Our findings showed that the plasma level of CK was increased in
257 response to exhaustive exercise, however, PRP administration did not alter CK levels in the PRP
258 group compared to control. Hence, intramuscular PRP injection did not show myotoxicity in
259 exercise-induced model.

260 **5. Conclusion**

261 Our study results indicate that an acute exhaustive exercise increased muscle damage
262 markers, including plasma iron, IBC and ferritin levels, indicate muscle damage due to exercise-
263 induced. PRP administration improved the inflammatory response by reversing the observed
264 increase in iron levels and may have a role to play in the recovery of exercise-induced muscle
265 damage. Evidently, intramuscular PRP injection had no effect on CK levels, indicating that it is not
266 myotoxic.

267

268 **Conflict of interest**

269 There are no conflicts of interest including financial, personal or other relationships with
270 other organizations.

271 **Acknowledgements**

272 The authors would like to thank the volunteers who took part in this study.

273

274 **References**

- 275 1. Gosens T, Peerbooms JC, van Laar W, den Ouden BL. Ongoing positive effect of platelet-
276 rich plasma versus corticosteroid injection in lateral epicondylitis: a double-blind randomized
277 controlled trial with 2-year follow-up. *Am J Sports Med* 2011;39(6):1200-08.
- 278 2. Peerbooms JC, Sluimer J, Bruijn DJ, Gosens T. Positive effect of an autologous platelet
279 concentrate in lateral epicondylitis in a double-blind randomized controlled trial: platelet-rich
280 plasma versus corticosteroid injection with a 1 year follow-up. *Am J Sports Med* 2010;38:255-
281 62.
- 282 3. Grotendorst GR, Martin GR, Pencev D, Sodek J and Harvey AK. Stimulation of granulation-
283 tissue formation by platelet-derived growth-factor in normal and diabetic rats. *J Clin Invest*
284 1985; 76:2323–29.
- 285 4. Allen DG. Eccentric muscle damage: mechanisms of early reduction of force. *Acta Physiol*
286 *Scand* 2001;171:311-19.
- 287 5. Malm C. Exercise-induced muscle damage and inflammation: Fact or fiction? *Acta Physiol*
288 *Scand* 2001;171:233–39.
- 289 6. Ahmetov II, Naumov VA, Donnikov AE, Maciejewska-Karłowska A, Kostyukova ES, Larin
290 AK, Maykova EV, Alexeev DG, et al. SOD2 gene polymorphism and muscle damage markers
291 in elite athletes. *Free Radic Res* 2014;28:1-18. [Epub ahead of print].

- 292 7. Córdova MA, Martorell PM, Sureda GA, Tur Marí JA, Pons BA. Changes in circulating
293 cytokines and markers of muscle damage in elite cyclists during a multi-stage competition.
294 *Clin Physiol Funct Imaging* 2014; 26. doi: 10.1111/cpf.12170. [Epub ahead of print].
- 295 8. Clarkson PM, Hubal MJ. Exercise-induced muscle damage in humans. *Am J Phys Med*
296 *Rehabil* 2002; 81 (11, Suppl) S52–S69.
- 297 9. Tidball JG, Villalta SA. Regulatory interactions between muscle and the immune system
298 during muscle regeneration. *The Am J Physiol Regul Integr Comp Physiol* 2010;298(5): 1173–
299 87.
- 300 10. Peeling P, Dawson B, Goodman C, Landers G, Wiegerinck ET. Training surface and intensity:
301 Inflammation, hemolysis, and hepcidin expression. *Med Sci Sports Exerc* 2009; 41:1138–45.
- 302 11. Peeling P, Dawson B, Goodman C, Landers G, Wiegerinck ET, Swinkels DW, Trinder D.
303 Cumulative effects of consecutive running session on hemolysis, inflammation and hepcidin
304 activity. *Eur J Appl Physiol* 2009;106: 51–9.
- 305 12. Peeling P, Dawson B, Goodman C, Landers G, Wiegerinck ET, Swinkels DW, Trinder D.
306 Effects of exercise on hepcidin response and iron metabolism during recovery. *Int J Sport Nutr*
307 *Exerc Metab* 2009;19:583–97.
- 308 13. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T. IL-6 mediates
309 hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone
310 hepcidin. *J Clin Invest* 2004a;113 (9):1271–76.
- 311 14. Kemna E, Pickkers P, Nemeth E, van der Hoeven, Swinkels D. Time-course analysis of
312 hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. *Blood*
313 2005;106 (5):1864–66.

- 314 15. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Ward DM, Ganz T, Kaplan J. Heparin
315 regulates cellular iron efflux by binding to ferroportin and inducing its internalisation. *Science*
316 2004b; 306(5704):2090–93.
- 317 16. Clarkson PM, Sayers SP. Etiology of exercise-induced Muscle damage. *Can J Appl Physiol*
318 1999;24:234–48.
- 319 17. Cleak M, Eston R. Muscle soreness, swelling, stiffness and strength loss after intense eccentric
320 exercise. *Br J Sports Med* 1992;26:267–72.
- 321 18. Cheung KH, Patria A, Maxwell L. Delayed onset muscle soreness: treatment strategies and
322 performance factors. *Sports Med* 2003;33(2):145-64.
- 323 19. Almekinders LC. Anti-inflammatory treatment of muscular injuries in sport. An update of
324 recent studies. *Sports Med* 1999;28(6):383-8.
- 325 20. Paulsen G, Egner IM, Drange M, Langberg H, Benestad HB, Fjeld JG, Hallen J, Raastad T. A
326 COX-2 inhibitor reduces muscle soreness, but does not influence recovery and adaptation after
327 eccentric exercise. *Scand J Med Sci Sports* 2010;20(1):195-207.
- 328 21. Zhang J, Clement D, Taunton J. The efficacy of Farabloc, an electromagnetic shield,
329 inattenuating delayed-onset muscle soreness. *Clin J Sport Med* 2000;10(1):15-21.
- 330 22. Schonfeld BJ. The use of nonsteroidal anti-inflammatory drugs for exercise-induced muscle
331 damage: implications for skeletal muscle development. *Sports Med* 2012;42(12):1017-28.
- 332 23. Reuink G, Goudswaard GJ, Moen MH, Weir A, Verhaar JA, Tol JL. Myotoxicity of injections
333 for acute muscle injuries: a systematic review. *Sports Med* 2014;44(7):943-56.
- 334 24. Zink W, Graf BM. Local anesthetic myotoxicity. *Reg Anesth Pain Med* 2004;29:333–40.
- 335 25. Blom L, Rasmussen F. Tissue damage at the infection site after intramuscular injection of
336 drugs in hens. *Br Poult Sci* 1976;17:1–4.

- 337 26. Nosaka K, Sakamoto K. Changes in plasma enzyme activity after intramuscular injection of
338 bupivacaine in to the human biceps brachii. *Acta Physiol Scand* 1999;167:259–65.
- 339 27. Diness V. Local tissue damage after intramuscular injections in rabbits and pigs: quantitation
340 by determination of creatine kinase activity at injection sites. *Acta Pharmacol Toxicol*
341 1985;56:410-15.
- 342 28. Nyska A, Skolnick M, Ziv G, Gulkarov A. Correlation of injection site damage and serum
343 creatine kinase activity in turkeys following intramuscular and subcutaneous administration of
344 norfloxacin nicotinate. *Avian Pathol* 1994;23(4):671–82.
- 345 29. Hammond JW, Hinton RY, Curl LA, Muriel JM, Lovering RM. Use of autologous platelet-
346 rich plasma to treat muscle strain injuries. *Am J Sports Med* 2009;37(6):1135–42.
- 347 30. Harris NL, Huffer WE, von Stade E, Larson AI, Phinney S, Purnell ML. The effect of platelet
348 rich plasma on normal soft tissues in the rabbit. *J Bone Joint Surg Am* 2012;94(9):786–93.
- 349 31. Wright-Carpenter T, Opolon P, Appell HJ, Meijer H, Wehling P, Mir LM. Treatment of
350 muscle injuries by local administration of autologous conditioned serum: animal experiments
351 using a muscle contusion model. *Int J Sports Med* 2004;25(8):582–87.
- 352 32. Semark A, Noakes TD, Gibson ASC, Lambert MI. The effect of a prophylactic dose of
353 flurbiprofen on muscle soreness and sprinting performance in trained subjects. *J Sports Sci*
354 1999;17(3):197-203.
- 355 33. Kuipers H, Keizer HA, Verstappen FT, Costill DL. Influence of a prostaglandin-inhibiting
356 drug on muscle soreness after eccentric work. *Int J Sports Med* 1985;6(6):336-39.
- 357 34. Bourgeois J, MacDougall D, MacDonald JAY, Tarnopolsky M. Naproxen does not alter
358 indices of muscle damage in resistance-exercise trained men. *Med Sci Sports Exerc*
359 1999;31(1):4-9

- 360 35. Peeling P, Sim M, Badenhorst CE, Dawson B, Govus AD, Abbiss CR, Swinkels DW,
361 Trinder D. Iron status and the acute post-exercise hepcidin response in athletes. *Plos One*
362 2014;9(3):1-6
- 363 36. Takami T, Sakaida I. Iron regulation by hepatocytes and free radicals. *J Clin Biochem*
364 *Nutr* 2011;48(2):103-06.
- 365 37. Andia I, Maffulli N. Platelet-rich plasma for managing pain and inflammation in osteoarthritis.
366 *Nat Rev Rheumatol* 2013;9(12):721-30.
- 367 38. Zhang J, Middleton KK, Fu FH, Im HJ, Wang JH. HGF mediates the anti inflammatory effects
368 of PRP on injured tendons. *PLoS One* 2013;28:8(6):e67303.
- 369 39. Kim H, Lee Y. Biomarkers of muscle and cartilage damage and inflammation during a 200 km
370 run. *Eur J appl Physiol* 2007;99(4):443-47.
- 371 40. Butterfield TA, Best TM, Merrick MA. The dual roles of neutrophils and macrophages in
372 inflammation: A critical balance between tissue damage and repair. *J Athl Train* 2006;41:457-
373 65.
- 374 41. Sureda A, Tauler P. Antioxidant supplementation influences the neutrophil tocopherol
375 associated protein expression; but not the inflammatory response to exercise. *Cent Eur J Biol*
376 2007;2(1):56-70.
- 377 42. Evans WJ. Vitamin E, vitamin C, and exercise. *Am J Clin Nutr* 2000;72:647-52.
- 378 43. Sauerwein HP, Brouwer T, Dunning AJ. Creatine phosphokinase, myocardial infarction and
379 intramuscular injection. *Ned Tijdschr Geneeskd* 1975;119:1399-402.
- 380 44. Nosaka K, Sakamoto K. Changes in plasma enzyme activity after intramuscular injection of
381 bupivacaine into the human biceps brachii. *Acta Physiol Scand* 1999;167:259-65.